| ALN | Program | Spent | Major | Findings |
|---|---|---|---|---|
| 93.RD | Development of an oral available antiviral drug for yellow fever | $2.95M | Yes | 0 |
| 12.420 | MILITARY MEDICAL RESEARCH AND DEVELOPMENT | $730,086 | Yes | 0 |
| 93.395 | CANCER TREATMENT RESEARCH | $510,549 | Yes | 0 |
| 93.350 | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | $415,676 | Yes | 0 |
| 93.855 | ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH | $136,187 | Yes | 0 |
| 21.027 | COVID-19 - CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS | $113,939 | Yes | 0 |
| 93.RD | Investigation of the proviral effect of a novel host factor HLTF, an E3 ubiquitin ligase and DNA helicase, on the replication of hepatitis B virus | $7,752 | Yes | 0 |
| 93.837 | CARDIOVASCULAR DISEASES RESEARCH | $1,182 | Yes | 0 |
| Name | Title | Type |
|---|---|---|
| NAYCKSJB7F68 | Patti McAloon | Auditee |
| 2154894911 | Jimmy Mo | Auditor |
| No contacts on file | ||